Loading...
01/11 11:50
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed mixed financial performance with a decline in EBITDA and concerns over regulatory risks, particularly affecting LTAC. Despite positive growth in the Inpatient Rehab division and shareholder returns through dividends and stock repurchases, the company's high debt level and regulatory uncertainties pose significant risks. The Q&A highlighted management's unclear responses regarding mitigation strategies for regulatory impacts, adding to the negative sentiment. Given these factors and the market cap, a negative stock price movement is anticipated over the next two weeks.
Revenue Increased over 2% year-over-year; driven by strong performance in Inpatient Rehab division.
Adjusted EBITDA Declined by 9% from $165.8 million to $151.4 million year-over-year; impacted by challenges in Outpatient and Critical Illness Recovery divisions.
Earnings per common share Increased by 33% to $0.44 from $0.33 year-over-year; reflects improved performance in Inpatient Rehab.
Inpatient Rehab Revenue Increased by 16% year-over-year; strong growth in this division.
Inpatient Rehab Adjusted EBITDA Increased by 15% year-over-year; reflects operational efficiency.
Outpatient Revenue Increased by 1% year-over-year; driven by an increase in net revenue per visit despite challenges.
Outpatient Adjusted EBITDA Declined by 3% year-over-year; impacted by severe weather events and one less work day.
Critical Illness Recovery Revenue Decreased by 3% year-over-year; driven by a decline in rate per patient day and patient days.
Critical Illness Recovery Adjusted EBITDA Declined by 25% year-over-year; impacted by regulatory changes and challenges in patient volume.
Debt Outstanding $1.8 billion; includes $1.05 billion in term loans, $180 million in revolving loans, and $550 million in senior notes.
Interest Expense $29.1 million; decreased from $40.7 million year-over-year due to reduced debt.
Cash Flow from Operating Activities Used $3.5 million in cash flows; reflects operational challenges.
Cash on Balance Sheet $53.2 million; indicates liquidity position.
Day Sales Outstanding (DSO) 60 days; improved from 62 days year-over-year.
Capital Expenditures Used $52.3 million for property and equipment; reflects ongoing investments.
Stock Repurchases Repurchased 650,000 shares at an average price of $17.52 for a total of $11.4 million.
Dividends Declared a cash dividend of $0.0625 per share.
New Rehab Units: Opened a rehab unit in Madison, Wisconsin (18 beds) and a 12-bed unit in Tallahassee, Florida. Plans to open a 45-bed rehab hospital in Temple, Texas, and a 32-bed rehab hospital with Cleveland Clinic in Fairhill, Ohio.
Expansion Plans: Plans to open a 63-bed rehab hospital in Ozark, Missouri, and a 60-bed rehab hospital in Southern New Jersey by Q4 2026.
Outpatient Division Expansion: Added 10 de novo clinics, offset by the closure of 13 locations to optimize resources.
Operational Efficiency: Despite challenges, each division exceeded prior year adjusted EBITDA performance for March.
Financial Performance: Revenue increased over 2%, adjusted EBITDA declined by 9% from $165.8 million to $151.4 million.
Strategic Focus: Focusing on improving patient access, productivity, and investing in technology in the Outpatient division.
Stock Repurchase Program: Repurchased 650,000 shares at an average price of $17.52 for a total of $11.4 million.
Outpatient Division Challenges: The Outpatient division faced challenges due to severe weather events in the South and Central regions, which had an estimated impact of approximately $4 million. Additionally, there was a 3% reduction in Medicare reimbursement, amounting to about $2.6 million.
Critical Illness Recovery Hospital Challenges: The Critical Illness Recovery Hospital division was affected by a late start to the flu season and regulatory changes, including a significant increase in the high cost outlier threshold and the 20% Transmittal rule. These regulatory changes accounted for approximately two-thirds of the decline in EBITDA compared to the prior year.
Regulatory Risks: The company is facing ongoing regulatory risks, particularly with the proposed changes from CMS that could impact reimbursement rates and thresholds, including a potential increase in the high cost outlier threshold.
Economic Factors: The overall economic environment, including changes in Medicare reimbursement rates and the impact of severe weather events, poses risks to revenue and profitability.
Debt Management: The company has a significant debt load of $1.8 billion, which includes term loans and senior notes. Managing this debt while pursuing growth opportunities presents a financial risk.
Inpatient Rehab Division Growth: The Inpatient Rehab division had a very good first quarter and continues to exceed expectations, with significant growth anticipated for the foreseeable future.
Development Pipeline: Plans to open multiple new rehab facilities, including a 45-bed hospital in Temple, Texas, and a 63-bed hospital in Ozark, Missouri, among others, adding 440 additional beds from Q2 2025 through the end of 2027.
Outpatient Division Strategy: Focus on improving patient access, productivity, and investing in technology to enhance performance.
Stock Repurchase Program: Repurchased almost 650,000 shares at an average price of $17.52, totaling $11.4 million.
Revenue Guidance: Expected revenue for 2025 is in the range of $5.3 billion to $5.5 billion.
Adjusted EBITDA Guidance: Expected adjusted EBITDA for 2025 is in the range of $510 million to $530 million.
Earnings Per Share Guidance: Adjusted earnings per common share is expected to be in the range of $1.09 to $1.19.
Capital Expenditures Guidance: Capital expenditures are expected to be in the range of $160 million to $200 million.
Cash Dividend: The Board of Directors declared a cash dividend of $0.0625 per share payable on May 29, 2025, to stockholders of record as of the close of business on May 15, 2025.
Share Repurchase Program: During the quarter, we repurchased almost 650,000 shares of our stock at an average price per share of $17.52 for a total of $11.4 million under our Board authorized Stock Repurchase Program.
Despite strong financial metrics and expansion plans, the lack of raised guidance due to outpatient segment softness and unchanged EBITDA guidance offset positive impacts. The Q&A revealed pressures from Medicare rates and payer mix shifts, which may concern investors. The market cap suggests moderate stock price movement. Thus, a neutral rating is appropriate.
The earnings call presents a mixed picture: strong revenue growth in some divisions, but challenges in critical illness recovery. The reaffirmed guidance and strategic focus on joint ventures are positive. However, regulatory issues and unclear management responses about critical illness impact cast doubts. The stock repurchase is a positive sign, but the debt level and margin declines in some areas are concerning. Given the market cap and mixed signals, a neutral stock price reaction is expected.
The earnings call revealed mixed financial performance with a decline in EBITDA and concerns over regulatory risks, particularly affecting LTAC. Despite positive growth in the Inpatient Rehab division and shareholder returns through dividends and stock repurchases, the company's high debt level and regulatory uncertainties pose significant risks. The Q&A highlighted management's unclear responses regarding mitigation strategies for regulatory impacts, adding to the negative sentiment. Given these factors and the market cap, a negative stock price movement is anticipated over the next two weeks.
The earnings call presents a mixed outlook. Financial performance shows growth in revenue and EBITDA, but there are concerns with debt levels, declining margins in the inpatient rehab division, and operational challenges. The Q&A section highlights uncertainties, particularly around startup costs and margin impacts. Positive factors include revenue growth and optimistic guidance for new facilities, but high debt and lack of share repurchase are negative. Given the market cap, these mixed signals likely lead to a neutral stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
